

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
NEW DRUG APPLICATION FOR OT-1001 ACCEPTED BY THE
NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that the new drug application for OT-1001 (ZERViate), a potent and highly selective histamine-1 receptor antagonist with anti-allergic properties, has been accepted by the National Medical Products Administration of the People’s Republic of China on April 12, 2023.

OT-1001 (ZERViate) was developed by Nicox Ophthalmics, Inc. (“**Nicox**”). The Group obtained an exclusive license from Nicox to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell (or otherwise commercialize) OT-1001 (ZERViate) in the Greater China region in March 2019, and extended the exclusive rights to 11 countries in Southeast Asia in March 2020.

OT-1001 is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in ZYRTEC[®], and is currently commercialized in the United States for ocular itching associated with allergic conjunctivitis. In March 2022, the phase III clinical trial of OT-1001 (ZERViate) achieved its primary clinical endpoint and received positive results. OT-1001 (ZERViate) was found to be non-inferior to emedastine difumarate in the primary efficacy endpoint of change from baseline in the itching score in the 24 hours prior to the Day 14 visit. OT-1001 (ZERViate) was safe and well-tolerated with no difference in the proportion of patients with adverse events compared to emedastine difumarate.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-1001 (ZERVIAE) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, April 14, 2023

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.